35166-20-2

Basic information

• Product Name: Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)- (9CI)
• Synonyms: Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)- (9CI);1-(3,5-dimethylisoxazol-4-yl)ethanone
• CAS NO: 35166-20-2
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.15186
• Product Categories: ACETYLGROUP
• Mol File: 35166-20-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 233.797 °C at 760 mmHg
• Flash Point: 95.198 °C
• Appearance: /
• Density: 1.074 g/cm³
• Vapor Pressure: 0.055mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)- (9CI)(35166-20-2)
• EPA Substance Registry System: Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)- (9CI)(35166-20-2)

Safety Data

• Hazardous Substances Data: 35166-20-2(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)- (9CI) is a chemical compound with the molecular formula C8H11NO2. It is a derivative of isoxazole, a heterocyclic compound containing both nitrogen and oxygen atoms in its five-membered ring structure. Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)- (9CI) is commonly used in pharmaceutical research and can exhibit various biological activities due to its unique structure. It is important to handle this chemical with care and follow proper safety precautions when using it in laboratory settings.

InChI:InChI=1/C7H9NO2/c1-4-7(5(2)9)6(3)10-8-4/h1-3H3

Upstream product

• 546-88-3 acetylhydroxamic acid 
• 123-54-6 acetylacetone 
• 1223452-45-6 N-methoxy-N-methyl-3,5-dimethylisoxazole-4-carboxamide 
• 31301-45-8 3,5-dimethylisoxazole-4-carbonyl chloride 
• 75-16-1 methylmagnesium bromide 
• 59402-44-7 1-(3,5-dimethylisoxazol-4-yl)ethanol 
• 54593-26-9 3,5-dimethyl-1,2-oxazole-4-carbaldehyde 
• 19788-36-4 4-hydroxymethyl-3,5-dimethylisoxazole 
• 56328-87-1 methyl 3,5-dimethylisoxazole-4-carboxylate 
• 2510-36-3 3,5-dimethyl-4-isoxazolecarboxylic acid 
• 917-54-4 methyllithium 
• 31301-46-9 4-cyano-3,5-dimethylisoxazoline 
• 917-64-6 methyl magnesium iodide 

Downstream Products

• 23000-12-6 1-(2,5-dimethyloxazol-4-yl)ethanone 
• 85094-04-8 4-cinnamoyl-3,5-dimethylisoxazole 
• 1421838-38-1 methyl 2-(4-(2-(3,5-dimethylisoxazol-4-yl)-2-hydroxyethoxy)phenyl)acetate 
• 1421838-41-6 2-(4-(2-(3,5-dimethylisoxazol-4-yl)-2-oxoethoxy)phenyl)-N-((2,4-dimethylphenyl)(phenyl)methyl)acetamide 
• 1421837-32-2 C₃₀H₃₂N₂O₄ 
• 1421838-42-7 methyl 2-(1-(3,5-dimethylisoxazol-4-yl)-2-(4-(2-(((2,4-dimethylphenyl)(phenyl)methyl)amino)-2-oxoethyl)phenoxy)ethoxy)-2-methylpropanoate 
• 1421837-91-3 C₃₄H₃₈N₂O₆ 
• 1421838-37-0 methyl 2-(4-(2-(3,5-dimethylisoxazol-4-yl)-2-oxoethoxy)phenyl)acetate 
• 1616100-66-3 tert-butyl ((4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-yl)carbamate 
• 1616100-65-2 tert-butyl (4S,6S)-4-(5-bromo-2,4-difluorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-ylcarbamate 
• 1616100-64-1 (4S,6S)-4-(5-bromo-2,4-difluorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1585970-78-0 (R)-N-((S)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-oxobutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1585971-25-0 (R)-N-((2S,4R)-2-(5-bromo-2,4-difluorophenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-hydroxybutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1616100-22-1 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 

Relevant articles and documents

Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors

Inhibition of transforming growth factor β (TGF-β) type 1 receptor (ALK5) provides a feasible approach for the treatment of fibrotic diseases and malignant tumors. In this study, we designed and synthesized a new series of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives, and evaluated biologically as TGF-β type 1 receptor inhibitors. The most potent compound 15r inhibited the ALK5 enzyme and NIH3T3 cell viability with IC50 values of 44 and 42.5 nM, respectively. Compound 15r also displayed better oral plasma exposure and excellent bioavailability than LY-3200882, and in vivo inhibited 65.7% of the tumor growth in a CT26 xenograft mouse model.

Pyrimidinone Derivatives as Antimalarial Agents

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n = 0 or 1 and R2 is a methyl group when n = 0 and a hydrogen atom when n = 1. Process for the preparation thereof and therapeutic use thereof.